肺腺癌中3P_tRNA-Arg-TCT-4-1的表达及对增殖的影响
Expression of 3P_tRNA-Arg-TCT-4-1 in Lung Adenocarcinoma and Its Effect on Proliferation
DOI: 10.12677/acm.2024.1472055, PDF, HTML, XML, 下载: 3  浏览: 5 
作者: 何志鹤:扬州大学医学院病理学教研室,江苏 扬州;张家港市第二人民医院医院呼吸内科,江苏 张家港;王成海:扬州大学医学院病理学教研室,江苏 扬州;江苏省中西医结合老年病防治重点实验室,江苏 扬州
关键词: 肺腺癌3P_tRNA-Arg-TCT-4-1增殖活性临床特征Lung Adenocarcinoma 3P_tRNA-Arg-TCT-4-1 Proliferative Activity Clinical Features
摘要: 目的:研究肺腺癌(LUAC)中3P_tRNA-Arg-TCT-4-1的表达情况及其临床意义,并探索3P_tRNA-Arg-TCT-4-1对LUAC细胞生长和和生存预后的影响。方法:收集我院手术切除的LUAC 71例标本及临床特征。qRT-PCR检测3P_tRNA-Arg-TCT-4-1在LUAC组织中的表达水平,统计分析3P_tRNA-Arg-TCT-4-1的表达与LUAC病理特征的相关性。通过Kaplan-Meier统计方法分析3P_tRNA-Arg-TCT-4-1表达对肺腺癌患者生存预后的影响。采用CCK-8增殖实验检测3P_tRNA-Arg-TCT-4-1对LUAC细胞增殖的影响。结果:qRT-PCR实验结果显示,在71对LUAC组织中3P_tRNA-Arg-TCT-4-1相对表达量为3.491 ± 0.222,明显高于癌旁正常组织(t = 10.064, P = 0.000 < 0.05);统计分析结果显示3P_tRNA-Arg-TCT-4-1的表达与LUAC的分化程度(χ2 = 11.112, P = 0.001)和肿瘤大小(χ2 = 4.616, P = 0.032)密切相关(P均 < 0.05),而与患者年龄、性别、淋巴结转移和TNM分期之间无相关性(P均 > 0.05)。在与患者生存预后的关系上,3P_tRNA-Arg-TCT-4-1正常或阴性表达组总生存期时间明显长于高表达组(χ2 = 5.885, P = 0.002 < 0.05)。CCK-8增殖实验提示过表达3P_tRNA-Arg-TCT-4-1增强了LUCA细胞的增殖活性,而降低3P_tRNA-Arg-TCT-4-1表达则减弱了LUCA细胞的增殖活性(P均 < 0.05)。结论:在LUCA中3P_tRNA-Arg-TCT-4-1表达水平升高,是一个新的促进增殖的促癌基因;3P_tRNA-Arg-TCT-4-1有可能成为治疗生长旺盛的LUCA分子标志物。
Abstract: Objective: To investigate the expression of 3P_tRNA-Arg-TCT-4-1 in lung adenocarcinoma (LUAC) and its clinical significance, and to explore the effect of 3P_tRNA-Arg-TCT-4-1 on the growth, survival and prognosis of LUAC cells. Methods: The clinical features and specimens of 71 pairs of LUAC were collected. The expression level of 3P_tRNA-Arg-TCT-4-1 in LUAC tissues was detected by qRT-PCR, and the correlation between the expression of 3P_tRNA-Arg-TCT-4-1 and the pathological characteristics of LUAC was statistically analyzed. The effect of 3P_tRNA-Arg-TCT-4-1 expression on survival and prognosis of lung adenocarcinoma patients was analyzed by the Kaplan-Meier statistical method. The effect of 3P_tRNA-Arg-TCT-4-1 on the proliferation of LUAC cells was detected by the CCK-8 proliferation assay. Results: The results of qRT-PCR showed that the relative expression of 3P_tRNA-Arg-TCT-4-1 in 71 pairs of LUAC tissues was 3.491 ± 0.222, which was significantly higher than that in adjacent normal tissues (t = 10.064, P = 0.000 < 0.05). Statistical analysis showed that the expression of 3P_tRNA-Arg-TCT-4-1 was closely correlated with the differentiation degree of LUAC (χ2 = 11.112, P = 0.001) and tumor size (χ2 = 4.616, P = 0.032) (both P < 0.05). There was no correlation with age, sex, lymph node metastasis, and TNM stage (all P > 0.05). With survival and prognosis, the total survival time of the 3P_tRNA-Arg-TCT-4-1 expression group was significantly longer than that of the high expression group (χ2 = 5.885, P = 0.002 < 0.05). The proliferation experiment of CCK-8 suggested that overexpression of 3P_tRNA-Arg-TCT-4-1 enhanced the proliferation activity of LUCA cells while silencing expression of 3P_tRNA-Arg-TCT-4-1 decreased the proliferation activity of LUCA cells (P < 0.05). Conclusion: 3P_tRNA-Arg-TCT-4-1 expression level is increased in LUCA, which is a new oncogene promoting proliferation. 3P_tRNA-Arg-TCT-4-1 may be a LUCA molecular marker for the treatment of vigorous growth.
文章引用:何志鹤, 王成海. 肺腺癌中3P_tRNA-Arg-TCT-4-1的表达及对增殖的影响[J]. 临床医学进展, 2024, 14(7): 588-595. https://doi.org/10.12677/acm.2024.1472055

1. 引言

肺腺癌(lung adenocarcinoma, LUAC)是人类中最常诊断的癌症,在全球癌症发病率中排名第一[1] [2]。引发LUAC的病因包括吸烟、空气污染和职业性危险因数和遗传基因突变等[3]。尽管肺腺癌能够早发现和早诊,但其发生发展的生理机制和潜在生物标志物仍有待进一步阐明。

转运RNA (Transfer RNA, tRNA)作为一种非编码RNA,传统上被认为是蛋白质转化过程中的一种适配分子[4]。近年来,在大规模基因测序时发现了一类新的非编码小RNA,它们来源于tRNA前体或成熟序列,起名tRNA衍生片段(tRNA-derived fragments, TRDF) [5] [6]。与tRNA的随机降解不同,这些片段的发生是在特定tRNA修饰酶作用下进行精确位点切割而形成的新产物,长度为14~50 nt [7]。目前已有不多的文献表明知TRDF参与了一些肿瘤的增殖、凋亡、侵袭和转移等生物学过程[7]-[11],例如,TRF-3027 (tRNAGly-GCC)可能与rna诱导沉默复合物(RISCs)的重要组分AGO结合,阻断复制蛋白A1 (RPA1)抑制细胞增殖,调节DNA损伤反应[8]。3’-tsRNA-LeuCAG在体外快速分裂细胞,在小鼠原位肝细胞癌模型中能诱导细胞凋亡。它与mRNA (RPS28和RPS15)结合以增强其翻译,阻断了18s前核糖体RNA加工,导致40S核糖体亚基数量减少,从而诱导细胞凋亡[9]。在结直肠癌中5’tiRNA-Val-CAC促进了细胞的生长和增殖[10]。tRF/miR-1280通过抑制支持CSC表型的Notch信号通路抑制结直肠癌细胞的生长和转移[11]。本实验通过分析NCBI在线数据集GSE83527、GSE62182和GSE110907得到LUAC中差异表达的tRNA衍生片段,其中3P_tRNA-Arg-TCT-4-1表达水平上调,并在71例LUAC组织中得到验证。本实验旨在探讨3P_tRNA-Arg-TCT-4-1的表达、临床病理意义以及对增殖的影响。

2. 材料与方法

2.1. 临床标本

71例新鲜的LUCA组织来自我院胸外科手术切除患者,时间为2021年8月~2023年12月,患者年龄范围43~68岁,中位年龄为56岁。患者手术前均未行化疗或放疗处理。纳入标准:1) 经病理检查确诊为LUCA;2) 入组前未进行手术、化放疗等抗肿瘤治疗;3) 患者临床资料和随访资料完整。排除标准:1) 患有其他原发和转移性肿瘤;2) 合并有心肝肾等重要脏器功能障碍和血液系统疾病、免疫功能障碍。肿瘤分期参照第8版美国肿瘤联合会肺腺癌分期系统,分为I期18例、II期22例、III期31例。本研究经扬州大学附属医院伦理委员会批准,并与患者签署知情同意书。

2.2. 材料和细胞

3P_tRNA-Arg-TCT-4-1过表达和降低表达的质粒由云舟生物科技(广州)股份有限公司合成。质粒转染过程按Lipofectamine 2000试剂盒(Invitrogen公司)说明书步骤进行。肺腺癌细胞株NCI-H1975购买于中国科学院上海细胞库。

2.3. 细胞培养

NCI-H1975的培养基为含10%胎牛血清 + 90% DMEM培养基(Invitrogen公司),其中还包括100 U/ml青霉素和100 μg/ml链霉素(Invitrogen公司)抗生素。放置于37℃且含5% CO2细胞培养箱孵育。

2.4. qRT-PCR实验

总RNA提取试剂盒分离LUCA组织后,用Prime-Script RT Reagent (TAKARA)试剂盒进行逆转录,再用Quanta bio PerfeCta SYBR Green FastMix (艾普拜生物)进行qRT-PCR,按试剂说明书进行实验。

2.5. 细胞增殖活性实验

在指定的时间(12、24、48和72 h),用10 μL CCK-8溶液在96孔板中处理NCI-H1975细胞系,并在孔中再孵育1小时。最后,使用酶标仪评估450 nm处的吸光度。结果分析:增殖比率 = (降低表达/过表达3P_tRNA-Arg-TCT-4-1细胞实验组 − 无细胞对照)/(无敲低表达/过表达3P_tRNA-Arg-TCT-4-1细胞阴性对照 − 无细胞对照) × 100%。

2.6. 统计学分析

所有数据均采用GraphPad Prism 8.0和SPSS 16.0软件进行分析,计量数据用均数 ± 标准差(mean ± SD)表示,组间均数的比较采用t检验,计数资料采用χ2检验。通过Kaplan-Meier统计方法分析3P_tRNA-Arg-TCT-4-1表达对肺腺癌患者生存预后的影响。P < 0.05为差异有统计学意义。

3. 结果

3.1. LUCA组织中3P_tRNA-Arg-TCT-4-1的表达水平

图1显示,qRT-PCR实验结果显示在71对LUCA组织中3P_tRNA-Arg-TCT-4-1表达水平为3.400 ± 0.238,明显高于癌旁正常组织NC (其值设定为1) (t = 10.064, P = 0.000 < 0.05)。该实验提示3P_tRNA-Arg-TCT-4-1在LUCA中可能发挥促癌基因的作用。

Figure 1. Results of qRT-PCR experiment. The expression level of 3P_TRnA-ARG-CTT-4-1 was up-regulated in LUCA

1. qRT-PCR实验结果。3P_tRNA-Arg-TCT-4-1在LUCA中表达水平上调

3.2. 3P_tRNA-Arg-TCT-4-1表达与LUCA临床特征的关联性

按3P_tRNA-Arg-TCT-4-1表达水平分为两组:高表达组(54例,3P_tRNA-Arg-TCT-4-1表达水平高于对照组)和正常/低表达组(17例,3P_tRNA-Arg-TCT-4-1表达水平等于或低于对照组)。通过统计分析得出3P_tRNA-Arg-TCT-4-1的表达与LUCA的分化程度(χ2 = 11.112, P = 0.001)、肿瘤大小(χ2 = 4.616, P = 0.032)密切相关(P均 < 0.05),而与患者年龄、性别、肿瘤淋巴结转移和TNM分期之间无相关性(P均 > 0.05),见表1。这一结果提示高表达的3P_tRNA-Arg-TCT-4-1参与了肺癌细胞的分化和增殖过程。

Table 1. Relationship between expression of 3P_tRNA-Arg-TCT-4-1 in LUCA and clinical features

1. 肺腺癌组织3P_tRNA-Arg-TCT-4-1表达与临床特征的关系

指标

高表达组(n = 54)

正常/低表达组(n = 17)

χ2

P

性别

44

10

3.645

0.056

10

7

年龄

<55岁

18

6

0.022

0.882

≥55岁

36

11

肿瘤大小(直径)

≤5 cm

22

12

4.616

0.032

>5 cm

32

5

分化程度

中低分化

40

5

11.112

0.001

高分化

14

12

淋巴结转移

26

5

1.845

0.174

28

12

TNM分期

I~II期

30

10

0.056

0.813

III期

24

7

3.3. 3P_tRNA-Arg-TCT-4-1对肺癌细胞增殖活性的影响

正如2.2实验结果提示3P_tRNA-Arg-TCT-4-1与肿瘤直径大小(直径)密切相关,因此进一步通过CCK-8实验研究3P_tRNA-Arg-TCT-4-1对肺腺癌细胞增殖活性的影响。实验结果如图2显示:在72 h时,过表达3P_tRNA-Arg-TCT-4-1后NCI-H1975细胞的增殖活性为0.89 ± 0.03,明显高于对照组0.69 ± 0.02 (P < 0.05);而降低3P_tRNA-Arg-TCT-4-1表达后NCI-H1975细胞的增殖活性为0.56 ± 0.02,明显低于对照组0.70 ± 0.02 (P < 0.05)。该实验结果表明3P_tRNA-Arg-TCT-4-1能促进肺癌细胞的增殖活性,有助于肿瘤的生长。

Figure 2. Proliferative activity of CCK-8. (A) After overexpression of 3P_tRNA-Arg-TCT-4-1, proliferation activity of NCI-H1975 cells was increased (P< 0.05); (B) The proliferation activity of NCI-H19751 cells was decreased by decreasing the expression of 3P_tRNA-Arg-TCT-4-1 (P< 0.05)

2. CCK-8增殖活性实验。(A) 过表达3P_tRNA-Arg-TCT-4-1后,NCI-H1975细胞增殖活性升高(P < 0.05);(B) 降低3P_tRNA-Arg-TCT-4-1表达则NCI-H19751细胞增殖活性下降(P < 0.05)

3.4. 3P_tRNA-Arg-TCT-4-1表达对肺腺癌患者生存预后的影响

3P_tRNA-Arg-TCT-4-1高表达组中位Overall survival生存时间为22个月(四分位区间4~44个月),3P_tRNA-Arg-TCT-4-1正常或阴性表达组中位Overall survival为31个月(四分位区间9~50个月)。正常或阴性表达组Overall survival明显长于高表达组(χ2 = 5.885, P = 0.002 < 0.05),见图3

Figure 3. Survival curve of 3P_tRNA-Arg-TCT-4-1 expression and prognosis in patients with LUCA

3. 3P_tRNA-Arg-TCT-4-1表达与肺腺癌患者预后的生存曲线图

4. 讨论

肺癌已成为世界范围内的致命恶性肿瘤,主要组织病理学亚型为非小细胞肺癌和小细胞肺癌,而非小细胞肺癌的80%以上[1] [2]。肺腺癌(LUAD)是最常见的非小细胞肺癌亚型,5年生存率约为15% [1]。目前虽然在治疗肺癌上取得了很大的进展,其复发和耐药仍然没有得到有效控制,因此,探索新的诊断和治疗方法至关重要。

越来越多的证据表明,TRDFs调节细胞内基因转录、蛋白质翻译和表观遗传[7]-[11]。tRFs参与多种分子调控机制,如靶基因的miRNA样沉默、RNA加工和降解、组蛋白修饰、核糖体组装和活性以及未折叠蛋白反应[12] [13]。此外,TRDF在包括癌症等许多疾病中发挥关键作用[8]-[11]。例如,Ma等人[14]发现tRF-20-S998LO9D在乳腺浸润性癌、头颈部鳞状细胞癌、肾透明细胞癌、肺鳞状细胞癌、和子宫内膜癌等多种癌症中均有高表达。抑制tRF-20-S998LO9D导致乳腺癌(MCF-7)和肺鳞癌(sk-mes1)细胞的细胞增殖减少。在多种癌症中,tRF-20-S998LO9D升高预示预后不良。

在不同类型的肺癌中也有TRDFs的表达异常,例如,与健康个体相比,非小细胞肺癌(NSCLC)患者和早期NSCLC患者外泌体中tRF-Leu-TAA-005、tRF-Asn-GTT-010、tRF-Ala-AGC-036、tRF-Lys-CTT-049和tRF-Trp-CCA-057的表达水平显著降低;该结果这表明这五种外泌体TRDFs可能是NSCLC的有希望的诊断生物标志物[15]。Shi [16]等人通过分析三对LUAD组织中的TRDFs表达,发现tRF-29-79在LUAD中下调,而tRF-29-79的下调与较差的预后相关。功能上tRF-29-79可抑制LUAD细胞的增殖、迁移和侵袭。机制上tRF-29-79与RNA结合蛋白PTBP1相互作用,促进PTBP1从细胞核到细胞质的运输,从而调节SLC1A5 pre-mRNA的3'非翻译区(UTR)的选择性剪接,从而发挥其抗癌功能。Magesh [17]等人研究发现在吸烟诱导的肺鳞状细胞癌(LUSC)和非吸烟诱导的LUSC原发肿瘤样本中,TRDFs表达差异很大,表明烟草烟雾可能调节TRDFs表达,促进癌症的发生和发展。本实验通过分析NCBI在线数据集GSE83527、GSE62182和GSE110907得到LUAC中差异表达的tRNA衍生片段,其中3P_tRNA-Arg-TCT-4-1表达升高,然后对3P_tRNA-Arg-TCT-4-1在LUCA中的具体作用还尚未明了,这就是本文的研究所在。

本研究qRT-PCR实验提示在肺腺癌组织中3P_tRNA-Arg-TCT-4-1表达水平高于癌旁正常肺组织,提示3P_tRNA-Arg-TCT-4-1在肺腺癌的发生发展过程中起着促癌基因的作用。也说明了3P_tRNA-Arg-TCT-4-1作为TRDFs的一员,在肺腺癌的发生发展中发挥了重要的作用和功能。分析3P_tRNA-Arg-TCT-4-1与临床参数的关系上,统计分析发现高表达的3P_tRNA-Arg-TCT-4-1与肺腺癌的肿瘤直径大小、分化程度和生存预后密切相关,而与患者年龄、性别、淋巴结转移和TNM分期之间无相关性。这一结果表明,3P_tRNA-Arg-TCT-4-1参与了肺腺癌细胞的增殖和分化,即3P_tRNA-Arg-TCT-4-1在肺腺癌中表达水平越高,肿瘤细胞分化越低,越能生长增殖,且患者预后不佳,进一步说明3P_tRNA-Arg-TCT-4-1是一个促癌基因,可成为肺腺癌增殖和预后判断的生物标志物。TNM分期中的T代表原发肿瘤的大小和浸润深度,但本研究结果显示3P_tRNA-Arg-TCT-4-1表达与肺腺癌的TNM分期无关,但P = 0.056,也接近有统计学意义,这可能是本研究标本数量偏少有关,今后会进一步加大样本数目研究。另外通过CCK-8实验表明过表达3P_tRNA-Arg-TCT-4-1后,细胞的增殖活性升高;降低3P_tRNA-Arg-TCT-4-1表达后,细胞的增殖活性下降,再次提示3P_tRNA-Arg-TCT-4-1促进肺腺癌细胞的增殖活性,参与了肺腺癌的生长过程。

5. 结论

综上所述,3P_tRNA-Arg-TCT-4-1在肺腺癌组织中表达水平上调,与LUCA的肿瘤大小和生存预后密切相关;可以作为LUCA生长的标志物和预后判断的指标。本研究探讨了3P_tRNA-Arg-TCT-4-1在肺腺癌增殖过程和预后判断中的作用,为今后诊治生长旺盛的肺腺癌提供新策略。

参考文献

[1] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48.
https://doi.org/10.3322/caac.21763
[2] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
[3] Blechter, B., Chien, L., Chen, T., Chang, I., Choudhury, P.P., Hsiao, C., et al. (2023) Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan. JAMA Network Open, 6, e2339254.
https://doi.org/10.1001/jamanetworkopen.2023.39254
[4] Schimmel, P. (2017) The Emerging Complexity of the tRNA World: Mammalian tRNAs Beyond Protein Synthesis. Nature Reviews Molecular Cell Biology, 19, 45-58.
https://doi.org/10.1038/nrm.2017.77
[5] Yu, M., Lu, B., Zhang, J., Ding, J., Liu, P. and Lu, Y. (2020) tRNA-Derived RNA Fragments in Cancer: Current Status and Future Perspectives. Journal of Hematology & Oncology, 13, Article No. 121.
https://doi.org/10.1186/s13045-020-00955-6
[6] Tosar, J.P. and Cayota, A. (2020) Extracellular tRNAs and tRNA-Derived Fragments. RNA Biology, 17, 1149-1167.
https://doi.org/10.1080/15476286.2020.1729584
[7] Zhu, L., Ge, J., Li, T., Shen, Y. and Guo, J. (2019) tRNA-Derived Fragments and tRNA Halves: The New Players in Cancers. Cancer Letters, 452, 31-37.
https://doi.org/10.1016/j.canlet.2019.03.012
[8] Balatti, V., Pekarsky, Y. and Croce, C.M. (2017) Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy. Advances in Cancer Research, 135, 173-187.
https://doi.org/10.1016/bs.acr.2017.06.007
[9] Kim, H.K., Fuchs, G., Wang, S., Wei, W., Zhang, Y., Park, H., et al. (2017) A Transfer-RNA-Derived Small RNA Regulates Ribosome Biogenesis. Nature, 552, 57-62.
https://doi.org/10.1038/nature25005
[10] 周洁, 王磊, 王成海. 结直肠癌中5’tiRNA-Val-CAC对增殖的影响及病理意义[J]. 实用临床医药杂志, 2022, 26(12): 96-101.
[11] Huang, B., Yang, H., Cheng, X., Wang, D., Fu, S., Shen, W., et al. (2017) tRF/miR-1280 Suppresses Stem Cell-Like Cells and Metastasis in Colorectal Cancer. Cancer Research, 77, 3194-3206.
https://doi.org/10.1158/0008-5472.can-16-3146
[12] Shaukat, A., Kaliatsi, E.G., Stamatopoulou, V. and Stathopoulos, C. (2021) Mitochondrial tRNA-Derived Fragments and Their Contribution to Gene Expression Regulation. Frontiers in Physiology, 12, Article 729452.
https://doi.org/10.3389/fphys.2021.729452
[13] Wen, J., Huang, Z., Li, Q., Chen, X., Qin, H. and Zhao, Y. (2021) Research Progress on the tsRNA Classification, Function, and Application in Gynecological Malignant Tumors. Cell Death Discovery, 7, Article No. 388.
https://doi.org/10.1038/s41420-021-00789-2
[14] Ma, J. and Liu, F. (2022) Study of tRNA-Derived Fragment tRF-20-S998LO9D in Pan-Cancer. Disease Markers, 2022, Article 8799319.
https://doi.org/10.1155/2022/8799319
[15] Zheng, B., Song, X., Wang, L., Zhang, Y., Tang, Y., Wang, S., et al. (2022) Plasma Exosomal tRNA-Derived Fragments as Diagnostic Biomarkers in Non-Small Cell Lung Cancer. Frontiers in Oncology, 12, Article 1037523.
https://doi.org/10.3389/fonc.2022.1037523
[16] Shi, Y., Pan, Z., Feng, Y., Zhou, Q., Wang, Q., Wang, H., et al. (2024) tRF-29-79 Regulates Lung Adenocarcinoma Progression through Mediating Glutamine Transporter SLC1A5. Carcinogenesis, 45, 409-423.
https://doi.org/10.1093/carcin/bgae010
[17] Magesh, S., Gande, P., Yalamarty, R., John, D., Chakladar, J., Li, W.T., et al. (2023) Characterization of tRNA-Derived Fragments in Lung Squamous Cell Carcinoma with Respect to Tobacco Smoke. International Journal of Molecular Sciences, 24, Article 5501.
https://doi.org/10.3390/ijms24065501